Disrupting stroke-induced GAT-1-syntaxin1A interaction promotes functional recovery after stroke.

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Stroke is a leading cause of long-term disability, with limited therapeutic options for recovery.
• The interaction between GABA transporter 1 (GAT-1) and syntaxin1A (Synt1A) is implicated in stroke pathophysiology.
• Dysfunctional GAT-1 and reduced cortical excitability occur during the critical subacute phase post-stroke.

Purpose of the Study:

• To design and evaluate a small-molecule agent that promotes stroke recovery.
• To investigate the mechanism of action involving the dissociation of GAT-1 from Synt1A.
• To assess the therapeutic potential of novel compounds in preclinical stroke models.

Main Methods:

• Molecular design of GAT-1-Synt1A blockers based on their binding mechanism.
• In vitro and in vivo testing of compound potency and efficacy.
• Assessment of sensorimotor and cognitive function in rodent stroke models.
• Analysis of effects on GAT-1 dysfunction, cortical excitability, and synaptic function.

Main Results:

• A novel small molecule, ZLQ-3, was identified as a potent GAT-1-Synt1A blocker.
• Intranasal administration of ZLQ-3-1 (a derivative) significantly improved sensorimotor and cognitive deficits in rodent stroke models.
• The compound reversed stroke-induced GAT-1 dysfunction and normalized cortical excitability.
• Enhanced synaptic GABAergic inhibition and network plasticity were observed.

Conclusions:

• Dissociating GAT-1 from Synt1A is a viable strategy for promoting stroke recovery.
• ZLQ-3-1 demonstrates significant therapeutic potential as a stroke recovery agent.
• This approach offers a promising avenue for developing novel treatments to improve functional outcomes after stroke.